Global Abilify Maintena Market Size, Share and Trends Analysis Report, By Application (Schizophrenia, Bipolar Mania, and Major Depressive Disorder), and By Distribution Channel (Hospitals, Clinics, Drug Stores, and Others) Forecast (2022-2028)

The abilify maintena market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Abilify Maintena is a prescription medication for the treatment of schizophrenia, bipolar mania, and major depressive disorder symptoms. It can be used on its own or in combination with other drugs. It belongs to the antipsychotics, 2nd generation; antimanic agents’ class of medicines. According to the article published by American Addiction Centers Resource in 2022, schizophrenia is not a very common condition, but it may be a serious and chronic one. Schizophrenia affects only around 1% of the global population, and around 1.2% of Americans (3.2 million) experience this type of illness. In 2022, around 1.5 million people will be diagnosed with schizophrenia throughout the globe. In the US, this amounts to around 100,000 individuals being diagnosed with schizophrenia, or 7.2 persons per 1,000, or around 21,000 people in a metropolis of 3 million people.

The global abilify maintena market is segmented based on product application, and distribution channel. Based on application, the market is sub-segmented into schizophrenia, bipolar mania, and major depressive disorder. Based on the distribution channel, the market is sub-segmented into hospitals, clinics, drug stores, and others.

The market players are also contributing significantly to the market’s growth by adopting various strategies, including mergers and acquisitions, geographical expansion, partnerships, collaborations, and new product launches, to stay competitive in the market. For instance, in March 2021 Otsuka Pharmaceutical Canada Inc. and Lundbeck Canada Inc. stated that Health Canada had approved a notice of compliance for an abilify maintena alternate initiation regimen. Two injections of 400 mg abilify maintena of different gluteal and/or deltoid sites, followed by a single dosage of 20 mg oral aripiprazole, all on the first day of treatment, provide a novel option for patients starting abilify maintena.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Application
  • By Distribution Channel
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape– Otsuka Pharmaceuticals Co. Ltd., and Lundbeck A/S, among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Abilify Maintena Market Report by Segment

By Application

• Schizophrenia
• Bipolar Mania
• Major Depressive Disorder
• Others

By Distribution Channel

• Hospitals
• Clinics
• Drug Stores
• Others

Global Abilify Maintena Market Report by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa